ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Core Insights - ORIC Pharmaceuticals announced focused registrational clinical development plans for its lead programs, ORIC-944 and ORIC-114, and extended its cash runway into 2027, indicating a strong operational outlook [1][4][11] - The company expects to report five data readouts across its clinical programs over the next 15 months, with the initiation of registrational trials for both programs anticipated in 2026 [1][2][6] Financial Highlights - As of March 31, 2025, ORIC reported cash and investments totaling approximately $224 million, which is expected to fund its operating plan into 2027 [1][11] - Research and development (R&D) expenses for Q1 2025 were $24.6 million, an increase from $22.0 million in Q1 2024, attributed to higher external expenses and personnel costs [11][15] - General and administrative (G&A) expenses rose to $8.1 million in Q1 2025 from $7.0 million in Q1 2024, primarily due to increased personnel costs [11][15] Clinical Development Updates - ORIC-944, an allosteric inhibitor of PRC2, is set to initiate its first Phase 3 trial in metastatic castration-resistant prostate cancer (mCRPC) in the first half of 2026 [2][6] - ORIC-114, an irreversible EGFR/HER2 inhibitor, is being evaluated in a clinical trial in combination with subcutaneous amivantamab for first-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations [1][6] Upcoming Milestones - The company anticipates several key milestones, including combination dose escalation data for ORIC-944 in 1H 2025 and updated combination dose optimization data in 4Q 2025/1Q 2026 [11] - For ORIC-114, data for first-line EGFR exon 20 and other mutations is expected in 2H 2025, with additional data anticipated in mid-2026 [11]